diffuse reticulated skin hyperpigmentation in dystrophic epidermolysis bullosa

Original title: “Diffuse reticulated skin hyperpigmentation in dystrophic Epidermolysis bullosa.”

health related quality of life in recessive dystrophic epidermolysis bullosa findings of the prospective epidermolysis bullosa longitudinal evaluation study pebles

Original title: “Health-related quality of life in recessive dystrophic epidermolysis bullosa: findings of the Prospective Epidermolysis Bullosa Longitudinal Evaluation Study (PEBLES).”

recessive dystrophic epidermolysis bullosa in a resource limited setting a case report from mohamed adam sheikh children s teaching hospital hargeisa somaliland

Original title: “Recessive Dystrophic Epidermolysis Bullosa in a Resource-Limited Setting: A Case Report From Mohamed Adam Sheikh Children's Teaching Hospital Hargeisa, Somaliland.”

The session will focus on the latest ... III clinical trial, specifically highlighting the systemic disease-modifying capabilities of CORDStrom™ in patients with RDEB ... Unlike current standard-of-care options that are limited to topical wound treatments, CORDStrom™ is being developed as a systemic, disease-modifying therapy... The session will focus on the latest results from the MissionEB Phase III clinical trial, specifically highlighting the systemic disease-modifying capabilities of CORDStrom™ in patients with RDEB ... Unlike current standard-of-care options that are limited to topical wound treatments, CORDStrom™ is being developed as a systemic, disease-modifying therapy. Clinical investigators from the trial to share real-world experience treating RDEB patients with CORDStrom and present new data from the MissionEB clinical study Anna Martinez, MBBS, MRCP, FRCPCH - Principal investigator of the Mission EB Clinical trial. Dr. Martinez is the United Kingdom’s leading specialist in pediatric RDEB and is internationally recognized for her expertise in rare and complex skin disorders. Prof. Mark Lowdell, PhD, FRCPath FRSB - Chief Scientific Officer and Co-Founder of INmune Bio. Prof. Lowdell is also Professor of Cell and Tissue Therapy at University College London, where he has led a translational immunotherapy group since 1994.Registration Details INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has three product platforms: (1) CORDStrom™, a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that recently completed a blinded randomized trial in recessive dystrophic epidermolysis bullosa; (2) XPro™, a Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform designed to selectively neutralize soluble TNF, a key driver of inflammation and innate immune dysfunction; and (3) INKmune®, a cell-based medicine designed to prime a patient’s natural killer cells to eliminate minimal residual disease in patients with cancer.

Original title: “INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB | The Manila Times”